Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

746
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
746
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

798
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
798
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

687
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
687
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.4K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.4K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

4.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.5K
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

849
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
849

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phenylpropionamides of Cannabis sativa L. seeds exert a cytoprotective effect through modulation of the AMPK/mTOR/ULK1 autophagy pathway and attenuate apoptosis in MPP<sup>+</sup>-induced SH-SY5Y cells.

Tissue & cell·2026
Same author

A unified ligand-dimensional design to halt cation migration in perovskite photovoltaics.

Science advances·2026
Same author

Distinct metabolomic and lipidomic profiles across donation after circulatory death recovery strategies reveal a common signature associated with primary graft dysfunction.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same author

Intramyocardial Dissecting Hematoma After Myocardial Infarction Diagnosed by Multimodality Imaging.

JACC. Case reports·2026
Same author

RNA helicase associated with AU-rich elements (RHAU) regulates hepatic glucose homeostasis via a novel microRNA-150-Notch3-peroxisome proliferator-activated receptor γ pathway.

International journal of biological macromolecules·2026
Same author

Baseline characteristics of patients with transthyretin amyloidosis with cardiomyopathy in the CARDIO-TTRansform trial of eplontersen.

European journal of heart failure·2026

Related Experiment Video

Updated: Mar 28, 2026

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents
07:26

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Published on: July 14, 2021

5.7K

Sertad4 Regulates Pathological Cardiac Remodeling.

Ashley Francois1, Oscar Bermeo-Blanco2, Ba Thong Nguyen3

  • 1Department of Physiology & Cell Biology, Dorothy M. Davis Heart & Lung Research Institute, Ohio State University College of Medicine, Columbus, OH 43210.

Biorxiv : the Preprint Server for Biology
|March 27, 2026
PubMed
Summary

Sertad4 protein, increased in heart failure, drives cardiac fibrosis and remodeling. Its knockout in mice improved heart function after myocardial infarction, suggesting Sertad4 as a potential therapeutic target.

More Related Videos

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.8K
Mechanical Control of Relaxation Using Intact Cardiac Trabeculae
07:51

Mechanical Control of Relaxation Using Intact Cardiac Trabeculae

Published on: February 17, 2023

1.6K

Related Experiment Videos

Last Updated: Mar 28, 2026

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents
07:26

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Published on: July 14, 2021

5.7K
Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.8K
Mechanical Control of Relaxation Using Intact Cardiac Trabeculae
07:51

Mechanical Control of Relaxation Using Intact Cardiac Trabeculae

Published on: February 17, 2023

1.6K

Area of Science:

  • Cardiovascular Biology
  • Molecular Cardiology
  • Fibrosis Research

Background:

  • Cardiac fibrosis and myofibroblast activation contribute to heart failure.
  • Bromodomain and extra-terminal domain (BET) inhibition shows promise but faces toxicity concerns.
  • Sertad4 (SERTA domain containing protein 4) is a BRD4-dependent gene in cardiac fibroblasts, with an unknown role in heart pathology.

Purpose of the Study:

  • To investigate Sertad4 expression and function in human heart failure and murine myocardial infarction (MI).
  • To determine if Sertad4 plays a causal role in post-MI cardiac remodeling.

Main Methods:

  • Quantified SERTAD4 protein in human heart failure tissues.
  • Utilized Sertad4/LacZ reporter mice to track Sertad4 expression post-MI.
  • Performed single-nucleus RNA sequencing to identify cell-type-specific Sertad4 expression.
  • Generated and studied global Sertad4 knockout mice subjected to MI via LAD ligation.

Main Results:

  • SERTAD4 protein levels were elevated in human heart failure patients.
  • MI induced significant Sertad4 expression in fibroblasts within the infarct scar and border zone.
  • Sertad4 knockout mice showed attenuated post-MI remodeling, reduced hypertrophy, preserved systolic function, and decreased fibrosis markers.
  • Knockout hearts had smaller cardiomyocyte size and reduced expression of fibrosis/hypertrophy genes.

Conclusions:

  • Sertad4 is a fibroblast-enriched regulator of pathological cardiac remodeling.
  • Targeting Sertad4 may offer a cell-type-selective approach to mitigate cardiac fibrosis and heart failure progression.
  • Sertad4 inhibition presents a potential alternative to direct BET/BRD4 inhibition for treating heart conditions.